All In Biotech

NDA 016273 · Validus Pharms

Lasix

Furosemide · Oral · Loop Diuretic

NovelPriority reviewDiscontinued

Last checked: Nov 19, 2026Latest source record: Aug 8, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1966

Jul 1, 1966

Approved uses

1

Original approval plus efficacy supplements

Registered trials

345

66 Phase 3, 33 recruiting

FAERS reports

403,272

326,956 serious, 62,452 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2025.

INDICATIONS AND USAGE Edema LASIX is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. LASIX is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral LASIX may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with LASIX alone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 1, 1966 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • LASIX · FUROSEMIDE 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
  • LASIX · FUROSEMIDE 80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
  • LASIX · FUROSEMIDE 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Furosemide" as an intervention, any sponsor and status, largest first.

All 345 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea30,368
  • fatigue21,389
  • diarrhoea20,967
  • nausea19,527
  • acute kidney injury19,293
  • death18,972
  • fall16,731
  • pneumonia16,689
  • asthenia15,673
  • dizziness15,458
  • hypotension15,424
  • drug ineffective15,142

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046,745
20057,344
20067,622
20076,989
20087,496
20098,655
201010,679
201113,806
201214,534
201313,601
201420,395
201523,033
201626,335
201725,651
201829,730
201930,539
202027,196
202124,388
202221,088
202320,892
202421,765
202520,192
202614,575

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lasix (Furosemide)

2024 spending

$507K

Beneficiaries

2,262

6,667 claims

Per beneficiary

$224

$0.94 per unit

View as table
YearSpending
2020$1,023,684
2021$857,175
2022$718,838
2023$610,015
2024$507,435

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,449 on PubMed

Sponsor: Validus Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.